Discover this podcast and so much more

Podcasts are free to enjoy without a subscription. We also offer ebooks, audiobooks, and so much more for just $11.99/month.

Recently Approved Drugs: Durvalumab for patients with stage III Non-Small Cell Lung Cancers (NSCLC)

Recently Approved Drugs: Durvalumab for patients with stage III Non-Small Cell Lung Cancers (NSCLC)

FromASCO Education


Recently Approved Drugs: Durvalumab for patients with stage III Non-Small Cell Lung Cancers (NSCLC)

FromASCO Education

ratings:
Length:
11 minutes
Released:
Jun 27, 2018
Format:
Podcast episode

Description

Rami Manochakian, M.D., a thoracic clinical oncologist at the Mayo Clinic in Florida, presents information on the recently approved drug in oncology, durvalumab for patients with stage III Non-Small Cell Lung Cancers (NSCLC) after the completion of radiation therapy.
Released:
Jun 27, 2018
Format:
Podcast episode

Titles in the series (100)

The ASCO Education Podcast features expert conversations on the most talked-about topics in oncology today from physician burnout, medical cannabis, COVID and cancer and more…